Back to Research Hub
BioMarin Pharmaceutical Inc.
BMRN
$57.91+1.36 (+2.40%)
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder;…
StreetsValue research for BioMarin Pharmaceutical Inc. (BMRN)
Members get the full report for BioMarin Pharmaceutical Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.